Get started
Author

Delphine Désigaud

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related ( ATR ) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2019 · Eve Combès, Augusto F. Andrade, et al. · Cancer Research · 71
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
2016 · L Marzi, E Combes, et al. · British Journal of Cancer · 54
PDF
Identification of distinct immune activation profiles in adult humans
2020 · Renaud Cezar, Audrey Winter, et al. · Scientific Reports · 6
PDF
Insulin resistance is linked to a specific profile of immune activation in human subjects
2021 · Renaud Cezar, Delphine Desigaud, et al. · Scientific Reports · 5
PDF
Characterization of patient-derived cardiac cells in Purkinje-related idiopathic ventricular fibrillation
2026 · Pauline Belhumeur, Vincent Fontaine, et al. · Archives of cardiovascular diseases
Data from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Data from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure 2 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure S3 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Table S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Table S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure 2 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure S3 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Supplementary Figure S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
2023 · Eve Combès, Augusto F. Andrade, et al.
Abstract 1779: Anti-Müllerian hormone type II receptor (AMHRII), a cancer target for GM103, a novel antibody-drug conjugate (ADC)
2018 · Olivier Dubreuil, Jean-Marc M. Barret, et al. · Cancer Research
Abstract A147: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells
2018 · Eve Combes, Augusto Faria Andrade, et al. · Molecular Cancer Therapeutics
Works count: 17
Citation count: 136
H-index: 4
I10-index: 2
Year
Topic
Type